Compare SPT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPT | GLSI |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.6M | 372.0M |
| IPO Year | 2019 | 2020 |
| Metric | SPT | GLSI |
|---|---|---|
| Price | $5.54 | $21.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $12.38 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.7M | 137.2K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $457,547,000.00 | N/A |
| Revenue This Year | $9.03 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $5.39 | $7.78 |
| 52 Week High | $24.74 | $34.10 |
| Indicator | SPT | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 37.89 |
| Support Level | N/A | $9.50 |
| Resistance Level | $7.39 | $30.02 |
| Average True Range (ATR) | 0.31 | 2.18 |
| MACD | 0.06 | -0.55 |
| Stochastic Oscillator | 15.75 | 7.00 |
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.